Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017550 | 0.73 | ADORA3 (0.50) | MKNK1EGLN2KLK7DYRK1APDE4A | |
| SCHEMBL11456589 | 0.71 | MKNK1 (0.42) | MKNK1EGLN2KLK7DYRK1APDE4A | |
| SCHEMBL31314234 | 0.68 | MKNK1 (0.47) | MKNK1EGLN2KLK7DYRK1APDE4A | |
| SCHEMBL4068982 | 0.66 | — | — | |
| SCHEMBL14639038 | 0.65 | MKNK1 (0.49) | MKNK1KLK7DYRK1A | |
| SCHEMBL22045741 | 0.65 | MKNK1 (0.49) | MKNK1EGLN2KLK7DYRK1APDE4A | |
| SCHEMBL2862103 | 0.65 | MKNK1 (0.49) | MKNK1KLK7DYRK1APDE4A | |
| SCHEMBL16376208 | 0.65 | ADORA3 (0.55) | — | |
| SCHEMBL84692 | 0.65 | MKNK1 (0.53) | MKNK1EGLN2KLK7DYRK1APDE4A | |
| SCHEMBL22510132 | 0.65 | MKNK1 (0.53) | MKNK1EGLN2KLK7DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884104-B2 | Such as (3R,4R)-1-Pyrimidin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-amine bis-trifluoroacetic acid salt | MERCK SHARP & DOHME CORP. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1796669-B1 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | MKNK1 2684/4885EGLN2 858/4885KLK7 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.